CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

CAR-T Cell Immunotherapy Clinical Trial

Official title:
Chimeric Antigen Receptor-Modified T Cells for GD2 Positive Recurrent and Metastatic Glioma

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.

Clinical Trial Description

Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen receptor aiming at GD2 antigen. After CAR-T cell infusion, At periodic intervals, the investigators will evaluate clinical symptoms Improved conditions of this disease.Through this study, the investigators will evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03252171
Study type	Interventional
Source	Fuda Cancer Hospital, Guangzhou
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	October 15, 2015
Completion date	August 15, 2016

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02575261` - CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients	Phase 1/Phase 2
Withdrawn	`NCT04406610` - CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients	Phase 1/Phase 2
Withdrawn	`NCT02723942` - CAR-T Cell Immunotherapy for HCC Targeting GPC3	Phase 1/Phase 2